MD20160130A2 - Anticorpi umanizaţi contra CEACAM1 - Google Patents

Anticorpi umanizaţi contra CEACAM1 Download PDF

Info

Publication number
MD20160130A2
MD20160130A2 MDA20160130A MD20160130A MD20160130A2 MD 20160130 A2 MD20160130 A2 MD 20160130A2 MD A20160130 A MDA20160130 A MD A20160130A MD 20160130 A MD20160130 A MD 20160130A MD 20160130 A2 MD20160130 A2 MD 20160130A2
Authority
MD
Moldova
Prior art keywords
humanized antibodies
antibodies against
against ceacam1
human
sequence
Prior art date
Application number
MDA20160130A
Other languages
English (en)
Russian (ru)
Inventor
Техила БЕН-МОСХЕ
Иайр ЗАПИР
Илана МАНДЕЛЬ
Галь МАРКЕЛЬ
Якоб ШАХТЕР
Рона ОРТЕНБЕРГ
Фрэнсис Джозеф Карр
Роберт Джордж Э. Холгейт
Тимоти Дэвид ДЖОНС
Original Assignee
Ccam Biotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ccam Biotherapeutics Ltd. filed Critical Ccam Biotherapeutics Ltd.
Publication of MD20160130A2 publication Critical patent/MD20160130A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Invenţia se referă la anticorpi umanizaţi, capabili de a se lega specific cu moleculele CEACAM 1 umane, care conţin mutaţii inverse ale secvenţei umane în secvenţă murină în regiunile variabile, care nu sunt CDR, şi secvenţele de polinucleotide care le codifică. De asemenea, sunt propuse compoziţii farmaceutice, care conţin aceşti anticorpi, precum şi metode pentru utilizarea lor în tratamentul şi diagnosticul tumorilor maligne şi al altor stări.
MDA20160130A 2014-04-27 2015-04-27 Anticorpi umanizaţi contra CEACAM1 MD20160130A2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461984786P 2014-04-27 2014-04-27
US201562099155P 2015-01-01 2015-01-01
PCT/IL2015/050433 WO2015166484A1 (en) 2014-04-27 2015-04-27 Humanized antibodies against ceacam1

Publications (1)

Publication Number Publication Date
MD20160130A2 true MD20160130A2 (ro) 2017-04-30

Family

ID=54358258

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160130A MD20160130A2 (ro) 2014-04-27 2015-04-27 Anticorpi umanizaţi contra CEACAM1

Country Status (24)

Country Link
US (2) US10550196B2 (ro)
EP (2) EP3137502B1 (ro)
JP (1) JP6805428B2 (ro)
KR (1) KR102452349B1 (ro)
CN (1) CN106573977B (ro)
AP (2) AP2016009564A0 (ro)
AU (1) AU2015254886A1 (ro)
BR (1) BR112016024972B1 (ro)
CA (1) CA2946262C (ro)
CL (1) CL2016002689A1 (ro)
CR (1) CR20160534A (ro)
DO (1) DOP2016000282A (ro)
EA (1) EA037613B1 (ro)
ES (1) ES2825080T3 (ro)
IL (1) IL248402B (ro)
MD (1) MD20160130A2 (ro)
MX (2) MX366359B (ro)
NI (1) NI201600162A (ro)
PE (1) PE20170764A1 (ro)
PH (1) PH12016502151A1 (ro)
PL (1) PL3137502T3 (ro)
SG (1) SG11201608772UA (ro)
SV (1) SV2016005307A (ro)
WO (1) WO2015166484A1 (ro)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
US11492386B2 (en) * 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
JP6993812B2 (ja) * 2016-08-17 2022-01-14 治範 小田 細胞傷害活性を向上させたリンパ球の培養方法及び該方法で得られた細胞傷害活性を向上させたリンパ球を含む細胞免疫治療剤
CN110475788A (zh) 2017-03-24 2019-11-19 财团法人牧岩生命科学研究所 抗ceacam1抗体及其应用
KR102019913B1 (ko) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
CN109663130B (zh) * 2017-10-13 2021-06-29 江苏恒瑞医药股份有限公司 Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
EP3906261A4 (en) * 2018-12-07 2022-12-21 The Brigham And Women's Hospital, Inc. HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES
JP2022514615A (ja) 2018-12-20 2022-02-14 アルバート アインシュタイン カレッジ オブ メディスン ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
JP2023501387A (ja) * 2019-11-07 2023-01-18 グリーン・クロス・コーポレイション Ｃｅａｃａｍ１の立体エピトープ、及びｃｅａｃａｍ１の立体エピトープに特異的に結合する抗ｃｅａｃａｍ１抗体又はその断片
EP3909601A1 (en) * 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
EP4615871A1 (en) 2022-11-10 2025-09-17 FameWave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6022958A (en) 1986-08-13 2000-02-08 Bayer Corporation cDNAs coding for members of the carcinoembryonic antigen family
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
GB9421405D0 (en) 1994-10-21 1994-12-07 Dow Chemical Co Low voc laminating formulations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
DE19852804C1 (de) 1998-11-16 1999-12-23 Christoph Wagener Beeinflussung der Angiogenese durch CD66a
AU6940700A (en) 1999-08-26 2001-03-19 Amy P. N Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
DE10016877A1 (de) 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
SE0002835D0 (sv) 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
EP1472276A4 (en) 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
US20030022292A1 (en) 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20060058257A1 (en) 2001-08-03 2006-03-16 Christoph Wagener Influencing angiogenesis using CD66a
US20050107324A1 (en) 2003-07-12 2005-05-19 Bennett C. F. Modulation of CEACAM1 expression
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
US20030190600A1 (en) 2002-04-05 2003-10-09 Dana-Faber Cancer Institute Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
CU23228A1 (en) 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
CN101972478B (zh) 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
KR20050073488A (ko) 2002-10-08 2005-07-13 이뮤노메딕스, 인코오포레이티드 Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법
WO2005050200A2 (en) 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
CA2572289A1 (en) 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
WO2007063424A2 (en) 2005-06-09 2007-06-07 Gal Markel The modulation of immunity and ceacam1 activity
US20090226444A1 (en) 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
CN103864893B (zh) 2007-07-27 2017-01-04 伊玛提克斯生物技术有限公司 免疫疗法的免疫抗原表位
WO2009033095A2 (en) * 2007-09-07 2009-03-12 Cisthera, Incorporated Humanized pai-1 antibodies
WO2009141679A2 (en) 2007-11-05 2009-11-26 Gal Markel Ceacam1 based point-of-care cancer diagnostic
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
KR20180077322A (ko) 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들
ES2753986T3 (es) 2009-07-21 2020-04-15 Tel Hashomer Medical Res Infrastructure & Services Ltd Un método de diagnóstico de cáncer
KR101528013B1 (ko) 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
WO2013054320A1 (en) * 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US9556271B2 (en) 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
CN104011925A (zh) 2011-12-27 2014-08-27 株式会社Lg化学 锂二次电池及其制备方法
US20150337037A1 (en) * 2012-06-05 2015-11-26 Msm Protein Technologies Human monoclonal antibodies against human chemokine receptor ccr6
EP3539563A1 (en) * 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
WO2014055967A2 (en) * 2012-10-05 2014-04-10 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
HK1213788A1 (zh) * 2012-10-12 2016-07-15 布里格姆及妇女医院股份有限公司 免疫應答的增强
WO2015075710A1 (en) * 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
PL3763387T3 (pl) * 2013-11-25 2024-07-29 Famewave Ltd Kompozycje zawierające przeciwciała anty-ceacam1 i anty-pd do terapii nowotworu
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
ES2755957T3 (es) * 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos

Also Published As

Publication number Publication date
CR20160534A (es) 2017-04-25
US10550196B2 (en) 2020-02-04
KR102452349B1 (ko) 2022-10-11
MX2016014048A (es) 2017-05-23
CL2016002689A1 (es) 2017-11-03
PL3137502T3 (pl) 2021-03-08
DOP2016000282A (es) 2017-02-15
IL248402A0 (en) 2016-11-30
AU2015254886A1 (en) 2016-11-03
ES2825080T3 (es) 2021-05-14
EA037613B1 (ru) 2021-04-21
KR20170003937A (ko) 2017-01-10
EP3137502A1 (en) 2017-03-08
US20170044270A1 (en) 2017-02-16
BR112016024972B1 (pt) 2024-02-20
AP2016009564A0 (en) 2016-11-30
WO2015166484A1 (en) 2015-11-05
EP3137502B1 (en) 2020-07-29
EP3137502A4 (en) 2017-11-29
PE20170764A1 (es) 2017-07-04
CA2946262A1 (en) 2015-11-05
JP2017522261A (ja) 2017-08-10
BR112016024972A2 (pt) 2017-10-24
AP2016009504A0 (en) 2016-10-31
SG11201608772UA (en) 2016-11-29
MX366359B (es) 2019-07-05
CN106573977A (zh) 2017-04-19
US11866509B2 (en) 2024-01-09
US20200277398A1 (en) 2020-09-03
SV2016005307A (es) 2017-07-24
JP6805428B2 (ja) 2021-01-06
EA201692148A1 (ru) 2017-03-31
NI201600162A (es) 2017-03-08
EP3766902A1 (en) 2021-01-20
MX2019008041A (es) 2019-08-29
CA2946262C (en) 2022-07-26
IL248402B (en) 2020-10-29
PH12016502151A1 (en) 2017-01-16
CN106573977B (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
MD20160130A2 (ro) Anticorpi umanizaţi contra CEACAM1
NI201700012A (es) Inhibidores de la proteina quinasa c y métodos de su uso
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
ZA202100721B (en) Anti-mesothelin antibodies
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201892241A1 (ru) Диарильные макроциклы в качестве модуляторов протеинкиназ
EA201792572A1 (ru) Антитела к ox40 и их применение
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
EA201890513A1 (ru) Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение
EA201790413A1 (ru) Антитела против tigit
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201891851A1 (ru) Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений
HK1231099A1 (en) Humanized antibodies against ceacam1
ECSP16090450A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)